ScholarIQanswers from OpenAlex & ORCID
István Albert
ResearcherPublications, citations & collaboration network
István Albert is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does István Albert have?
ScholarIQindexed works
István Albert has 193 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does István Albert have?
ScholarIQcitation count
István Albert has 18,863 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of István Albert?
ScholarIQh-index
István Albert has an h-index of 50 in OpenAlex.
What is the i10-index of István Albert?
ScholarIQi10-index
István Albert has an i10-index of 92 in OpenAlex.
What is the ORCID of István Albert?
ScholarIQorcid
The ORCID for István Albert is on the source record.
What is the OpenAlex record for István Albert?
ScholarIQopenalex
The OpenAlex for István Albert is on the source record.
What are the most-cited papers on István Albert?
ScholarIQmost cited works
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
Fei Li, Changtao Jiang, Kristopher W. Krausz, Yunfei Li, István Albert, Haiping Hao, Kristin Fabre, James B. Mitchell, Andrew D. Patterson, Frank J. Gonzalez
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Changtao Jiang, Cen Xie, Fei Li, Limin Zhang, Robert G. Nichols, Kristopher W. Krausz, Jingwei Cai, Yunpeng Qi, Zhong-Ze Fang, Shogo Takahashi, Naoki Tanaka, Dhimant Desai, Shantu Amin, István Albert, Andrew D. Patterson, Frank J. Gonzalez
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark J. McKeage, István Albert, György Losonczy, Martin Reck, Dae Seog Heo, Xiaolin Fan, Abderrahim Fandi, Giorgio V. Scagliotti